IBC’s 5th Annual Conference on Blood Substitutes

Bibliography

• TSAI AG, KERGER H, and INTAGLIETTA M: Microcircula-tory consequences of blood substitution with haemo-globin solutions. In: Red Blood Cell Substitutes. Rudolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998)69–78.
   Google Scholar
• Guideline for quality assurance in blood establish-ments 7/11 /95. Rockville MD Center for Biologics Research and Review/FDA (1995).
   Google Scholar
• STEHLING L, SIMON TL: The red blood cell transfusiontrigger: physiology and clinical studies. Arch. Pathol. Lab. Med. (1994) 118:429–434.
   PubMed Web of Science ®Google Scholar
• GOODNOUGH LT, VERBRUGGE D, VIZMEG K, RIDDELLJIV: Identifying elective orthopedic surgical patients transfused with amounts of blood in excess of need: the transfusion trigger revisited. Transfusion (1992) 32:648–653
   PubMed Web of Science ®Google Scholar
• WINSLOW RM: Oxygen transport, oxygen carriers and the transfusion trigger. In: Red Blood Cell Substitutes. Ru-dolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):37–68.
   Google Scholar
• MCCULLOUGH J: The nations changing blood supply system. JAMA (1993) 269:2239–2245
   PubMed Web of Science ®Google Scholar
• SIMON TL: The quantitative analysis of transfusion medicine. (1995) 35:799–800
   Google Scholar
• HOLMBERG JA: Potential use of red blood cell substi-tutes within the military. In: Red Blood Cell Substitutes. Rudolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):17–27.
   Google Scholar
• SCHREIBER GB, BUCSH MP, KLEINMAN SH, KORELITZ JJ: The risk of transfusion transmitted viral infections. New Engl. J. Med. (1996) 334:1685–1690.
   PubMed Web of Science ®Google Scholar
• HOLLAND PV: Viral infections and the blood supply. New Engl. J. Med. (1996) 334:1734–1735.
   PubMed Web of Science ®Google Scholar
• ZUCK TF: Away from the madding crowds. Transfusion (1993) 33:888–889.
   PubMed Web of Science ®Google Scholar
• FRATANTONI JC: Blood substitutes: unique regulatory aspects. In: Red Blood Cell Substitutes. Rudolph AS, Rabino-vici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):29–35.
   Google Scholar
• STOWELL CP, TOMASULO P: The impact of blood substi-tutes on blood banking worldwide. In: Red Blood Cell Substitutes. Rudolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):1–16.
   Google Scholar
• TEICHER BA, ARA G H, YUNG-NAN C et al: PEG haemo-globin effects on tumour oxygenation and radiosensi-tization. Radiation Oncol. Investig. Clin. Basic Res. (1996) 4 (5):200–210.
   Google Scholar
• TEICHER BA, ARA G, HERBST R et al: PEG haemoglobin: effects on tumour oxygenation and response to che-motherapy. In vivo (1997) 11:301–312.
   PubMedGoogle Scholar
• MOTTRAM JC, EIDINOW A: On the effect of anemia on the reactions of skin and of tumors to radium expo-sure. Br. J. Surg. (1932) 19:481–487
   Google Scholar
• VAUPEL P, KALLINOWSKI F, OKUNIEFF P: Blood flow, oxygen and nutrient supply and metabolic microenvi-ronment of human tumors: a review. Cancer Res. (1989) 49:6449–6465
   PubMed Web of Science ®Google Scholar
• GATENBY RA, KESSLER HB, ROSENBLUM JS et al: Oxygendistribution in squamous cell carcinoma metastases and its relationship to outcome of therapy. int. j Ra-diat. Oncol. Biol. Phys. (1988) 14:831–838.
   PubMed Web of Science ®Google Scholar
• BRADLEY R, SLOSHBERG S, NHO K et al: Production ofPEG modified bovine haemoglobin: economics and feasibility. Artif. Cells Blood Subs. Immob. Biotech. (1994) 22:657–667.
   PubMed Web of Science ®Google Scholar
• FLAIM SF: Medical and therapeutic application of per-flourocarbon based products. In: Red Blood Cell Substi-tutes. Rudolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):437–464.
   Google Scholar
• SPENCE RK: Perflourocarbons. In: Principles of Transfu-sion Medicine. Rossi EC, Simon TL, Moss GS, Gould SA (Eds.), Williams and Wilkins, Baltimore, USA (1996):189–196.
   Google Scholar
• GUO J, WHITE JA, BATZER HH: Intravenous perflubron emulsion administration improves the recovery of auditory evoked potentials after temporary brain stem ischemia in dogs. Neurosurgery (1995) 36:350–357.
   PubMed Web of Science ®Google Scholar
• IWASHITA Y: Haemoglobin conjugated with polyoxyethylene. In: Artificial Red Cells. Tsuchida E (Ed.), John Wiley and Sons New York, USA (1995):151–176.
   Google Scholar
• FISCHER SR, BONE HG, POWELL WC etal: Pyridoxylated haemoglobin polyoxyethylene conjugate does not re-store hypoxic pulmonary vasoconstriction in ovine sepsis. Crit. Care Med. (1991) 25:1551–1559.
   Web of Science ®Google Scholar
• FISCHER SR, DEYO DJ, BONE HG et al: Nitric oxide syn-thase inhibition restores hypoxic pulmonary vaso-constriction in sepsis. Am. J. Respir. Crit. Care Med. (1997) 156:833–839.
   PubMed Web of Science ®Google Scholar
• LIGHT WR, JACOB EE, RENTKO VT, GAWRYL MS: Use of HBOC-201 as an oxygen therapeutic in the preclinical and clinical setting. In: Red Blood Cell Substitutes Ru-dolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):421–436.
   Google Scholar
• ORRINGER EP, GONZALEZ PM, HACKNEY AC et al.: A phase I study of polymerized bovine haemoglobin (PNI-1) in adult patients with sickle cell disease not in crisis at time of study. In: Sickle Cell Disease and Thalas-semias. Beuzard Y, Lubin B, Rosa J (Eds.), John Libbey Euro-text, Montrose, USA (1995) 234:301–302.
   Google Scholar
• WAHR JA, LEVY JH, KINDSCHER J et al.: Hemodynamic effects of a bovine HBOC solution in surgical patients. Anesthesiology (1996) 85:A347.
   PubMed Web of Science ®Google Scholar
• ADAMSON JG, BONAVENTURA BJ, SONG SER et al.: HE2110LINK, an oxidized raffinose crosslinked haemo-globin based blood substitute. In: Red Blood Cell Substi-tutes. Rudolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):335–351.
   Google Scholar
• GOULD SA, SEHGAL LR, MOSS GS, SEHGAL HL: The clini-cal development of human polymerized haemoglobin. In: Red Blood Cell Substitutes. Rudolph AS, Rabinovici R, Fuerstein GZ (Eds.), Marcell Dekker, USA (1998):401–419.
   Google Scholar
• GOULD SA, SEHGAL LR, SEHGAL HL et al.: Clinical expe-rience with human polymerized haemoglobin. (ABSTR) Transfusion (1993) 33 (Suppl. 9S):60S.
   Google Scholar
• GOULD S, MOORE E, MOORE F et al.: The clinical utility of human polymerized haemoglobin as a blood substi-tute following trauma and emergent surgery. J. Trauma (1995) 39:157.
   Google Scholar
• GOULD S: Human polymerized haemoglobin first therapeutic use as a blood substitute in trauma and surgery. American college of Surgeons 81st Clinical Con-gress. New Orleans, LA, USA (1995) Oct 22–27.
   Google Scholar
• NELSON DJ: HemAssist: development and clinical pro-file. In: Red Blood Cell Substitutes. Rudolph AS, Rabinovici R, Feuerstein GZ (Eds.), Marcell Dekker, USA (1998):353–400.
   Google Scholar
• VANDEGRIFF KD, ROHLFS RJ, WINSLOW RM: Colloid os-motic effects of haemoglobin based oxygen carriers. In: Advances in Blood Substitutes: Industrial Opportunities and Medical Challenges. Winslow RM, Vandegriff KD, Intalietta M (Eds.), Birkhauser, Boston, MA, USA (1997)207–223.
   Google Scholar